AIM
CORT icon

Allen Investment Management’s Corcept Therapeutics CORT Stock Holding History

Allen Investment Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$209K Buy
+2,400
New +$145K ﹤0.01% 226

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Allen Investment Management's CORT Position: Q2 2026 in Review

Allen Investment Management opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 2,400 shares worth $209K. The stake represents ﹤0.01% of the portfolio and ranks #226 among its holdings.

188 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Allen Investment Management held 2,400 shares of Corcept Therapeutics worth $209K as of Q2 2026.
  • Corcept Therapeutics was a new Allen Investment Management position in Q2 2026.
  • Corcept Therapeutics made up ﹤0.01% of Allen Investment Management's portfolio in Q2 2026, its #226 holding.
  • 188 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Allen Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.